secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001437749-25-033600
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares
--------------------------------------------------------------------------------

- Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.
- First closings Nov 4 & 6 generated ~$12.6M; second expected by Nov 18 for remaining 350,000 warrants.
- Issued new unregistered Series A warrants to purchase up to 11,326,364 shares at $2.05, 24-month term.
- Proceeds to fund working capital and accelerate development of PH-762 for cutaneous carcinomas.
- H.C. Wainwright acting as placement agent; fees include 7.5% cash fee and placement agent warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/0001437749-25-033600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/phio20251029_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-033600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer